Aging is a primary risk factor for neurodegenerative diseases, including Alzheimer's disease (AD). Accumulating evidence demonstrates that impaired autophagy contributes to cellular senescence, protein aggregation, mitochondrial dysfunction, and chronic neuroinflammation—hallmarks of aging and age-related neurodegeneration. Dysfunctional autophagic clearance accelerates the accumulation of toxic protein aggregates such as amyloid-beta (Aβ) and tau, thereby driving disease progression. Targeting autophagy to restore proteostasis and cellular homeostasis has therefore emerged as a promising anti-aging therapeutic strategy for preventing and treating aging-related neurodegenerative diseases.
Fig. 1 Simplified schematic of the role of aging in neurodegeneration. (Palmer JE, et al., 2025)
CD BioSciences provides specialized autophagy analysis services to support mechanistic studies and therapeutic development in aging-related neurodegenerative disorders. Our services focus on evaluating autophagic dysfunction during aging and assessing autophagy-targeted interventions in relevant disease models.
How Do We Analyze the Role of Autophagy in Aging-Related Neurodegenerative Diseases?
Analysis of autophagy dysfunction in aging-related neurodegenerative diseases
CD BioSciences provides comprehensive autophagy analysis services to evaluate age-dependent alterations in autophagy flux, autophagosome–lysosome dynamics, and lysosomal function in cellular and animal models of neurodegeneration. We assess the accumulation and clearance of disease-associated protein aggregates, including misfolded and aggregation-prone proteins, and analyze the regulation of core autophagy signaling pathways such as mTOR and AMPK. Our services enable mechanistic characterization of how autophagy dysfunction contributes to neuronal aging and progressive neurodegeneration.
Biomarker discovery services in autophagy impairment
Autophagy-related molecular alterations represent promising biomarkers for aging-related neurodegenerative diseases. We provide integrated molecular profiling and quantitative analysis to identify and validate biomarkers reflecting autophagy impairment during aging. Our services include the evaluation of gene and protein expression patterns, post-translational modifications, lysosomal enzyme activity, and autophagy flux indicators in disease-relevant models. These data support early detection strategies, disease stratification, and the monitoring of therapeutic responses in aging-related neurodegenerative diseases.
Evaluation of autophagy-targeted therapeutic strategies
Restoration of autophagic function is increasingly recognized as a rational anti-aging strategy to delay or mitigate neurodegenerative progression. CD BioSciences supports the preclinical evaluation of pharmacological interventions designed to modulate autophagy in models of aging-related neurodegeneration. We perform comprehensive assessments of autophagy activation or inhibition, downstream signaling modulation, and disease-relevant functional outcomes, including neuronal survival, protein aggregate clearance, and inflammatory responses. Our platforms also support the evaluation of therapeutic efficacy, safety, and toxicity profiles, providing robust datasets to advance autophagy-targeted drug discovery and development.
Why Choose CD BioSciences?
- Strong expertise in autophagy biology and aging mechanisms
- Dedicated analysis platforms for aging-related disease models
- Customized experimental design aligned with therapeutic development goals
- High-quality, quantitative, and reproducible datasets
CD BioSciences is committed to supporting research and drug development efforts targeting autophagy as an anti-aging strategy for aging-related neurodegenerative diseases. If you are interested in our services, please feel free to contact us or make an online inquiry.
References
- Palmer JE, et al. Autophagy, aging, and age-related neurodegeneration. Neuron, 2025, 113 (1): 29-48.
- Uddin MS, et al. Autophagy and Alzheimer's Disease: From Molecular Mechanisms to Therapeutic Implications. Front Aging Neurosci, 2018, 10: 004.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
